{"id":12703,"date":"2023-04-19T23:37:19","date_gmt":"2023-04-19T22:37:19","guid":{"rendered":"https:\/\/www.gecp.pt\/?p=12703"},"modified":"2023-04-19T23:37:19","modified_gmt":"2023-04-19T22:37:19","slug":"tratamento-de-cpnpc-egfr-mutado-na-era-do-osimertiniben","status":"publish","type":"post","link":"https:\/\/www.gecp.pt\/en\/tratamento-de-cpnpc-egfr-mutado-na-era-do-osimertiniben\/","title":{"rendered":"Treatment of mutated CPNPC EGFR in the osimertinib era"},"content":{"rendered":"<p>The Doctor. Ant\u00f3nio Calles was one of the speakers at the session &#8220;Hot Topics in CPNPC Therapeutics&#8221;, having presented the theme &#8220;Treatment of CPNPC mutated EGFR in the era of osimertinib&#8221;.<\/p>\n<p>Cross-border perspectives are always an asset at events of the size and importance of the 10th GECP Congress\/ 1st Portuguese Lung Cancer Congress and the contribution of Dr. Ant\u00f3nio Calles was no exception. For the expert &#8220;early inhibition of treatment with osimertinib ensures a better response duration, better progression-free survival, more intracranial activity and, above all, longer survival&#8221;.<\/p>\n<p>Get to know the expert&#8217;s statements by watching the video.<\/p>\n<!--themify_builder_content-->\n<div id=\"themify_builder_content-12703\" data-postid=\"12703\" class=\"themify_builder_content themify_builder_content-12703 themify_builder tf_clear\">\n                    <div  data-lazy=\"1\" class=\"module_row themify_builder_row tb_tk6j528 tb_first tf_w\">\n                        <div class=\"row_inner col_align_top tb_col_count_1 tf_box tf_rel\">\n                        <div  data-lazy=\"1\" class=\"module_column tb-column col-full tb_xi0a528 first\">\n                    <!-- module video -->\n<div  class=\"module module-video tb_pdi0538 video-top\" data-lazy=\"1\">\n                    <div class=\"video-wrap-outer\">\n            <div class=\"video-wrap tf_rel tf_overflow\">\n                                    <noscript><iframe data-no-script src=\"https:\/\/www.youtube.com\/embed\/atTCU0BUljs?pip=1&#038;playsinline=1\" allow=\"accelerometer;encrypted-media;gyroscope;picture-in-picture;fullscreen\" class=\"tf_abs tf_w tf_h\"><\/iframe><\/noscript>\n                                <\/div>\n            <!-- \/video-wrap -->\n        <\/div>\n        <!-- \/video-wrap-outer -->\n            <\/div>\n        <\/div>\n                        <\/div>\n        <\/div>\n        <\/div>\n<!--\/themify_builder_content-->\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>The Doctor. Ant\u00f3nio Calles was one of the speakers at the session &#8220;Hot Topics in CPNPC Therapeutics&#8221;, having presented the theme &#8220;Treatment of CPNPC mutated EGFR in the era of osimertinib&#8221;. Cross-border perspectives are always an asset at events of&#8230;<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>","protected":false},"author":1,"featured_media":12709,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0},"categories":[119,118,160],"tags":[],"_links":{"self":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/12703"}],"collection":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/comments?post=12703"}],"version-history":[{"count":4,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/12703\/revisions"}],"predecessor-version":[{"id":12710,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/posts\/12703\/revisions\/12710"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/media\/12709"}],"wp:attachment":[{"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/media?parent=12703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/categories?post=12703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gecp.pt\/en\/wp-json\/wp\/v2\/tags?post=12703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}